Comparative Pharmacology
Head-to-head clinical analysis: CARVEDILOL PHOSPHATE versus METOPROLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARVEDILOL PHOSPHATE versus METOPROLOL.
CARVEDILOL PHOSPHATE vs Metoprolol
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive beta-blocker with alpha1-blocking activity; decreases cardiac output, reduces peripheral vascular resistance.
Selective beta-1 adrenergic receptor antagonist; competitively blocks beta-1 receptors in the heart, decreasing heart rate, contractility, and cardiac output; reduces renin release from kidneys.
6.25 mg orally twice daily, titrated up to a maximum of 25 mg twice daily for heart failure; 12.5 mg orally once daily for hypertension, titrated to 25-50 mg daily.
Metoprolol tartrate: Initial 50 mg PO BID or 100 mg PO daily; maintenance 100-450 mg/day in divided doses. Metoprolol succinate (extended-release): Initial 25-100 mg PO once daily; maintenance 100-400 mg once daily.
None Documented
None Documented
Clinical Note
moderateMetoprolol + Digoxin
"Metoprolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateMetoprolol + Digitoxin
"Metoprolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateMetoprolol + Deslanoside
"Metoprolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateMetoprolol + Acetyldigitoxin
"Metoprolol may increase the bradycardic activities of Acetyldigitoxin."
7-10 hours (terminal elimination half-life); clinical context: supports twice-daily dosing for sustained beta-blockade.
3–7 hours for metoprolol; prolonged in poor CYP2D6 metabolizers (up to 8–16 hours). Clinical context: dosing interval typically twice daily (immediate-release) or once daily (extended-release).
Primarily hepatic metabolism (CYP2D6 and CYP2C9) followed by biliary excretion into feces; ~60% fecal elimination as metabolites, ~16% renal elimination of unchanged drug plus metabolites.
Primarily hepatic metabolism (CYP2D6) producing inactive metabolites; renal excretion accounts for <5% unchanged. Fecal elimination minimal.
Category C
Category C
Alpha/Beta-Blocker
Beta-Blocker